Aclarion Inc 最大收入来源是 Delivery of Nociscan Reports,在最近的收益报告中收入为 45,724。就地区而言, United States 是 Aclarion Inc 的主要市场,收入为 29,720。
Aclarion Inc 是否盈利?
不,根据最新的财务报表,Aclarion Inc 的净损失为 $-7
Aclarion Inc 有负债吗?
是的,Aclarion Inc 的负债为 1
Aclarion Inc 的流通股有多少?
Aclarion Inc 的总流通股为 0
关键数据
前收盘价
$3.41
开盘价
$3.32
当日区间
$3.3 - $3.61
52周范围
$2.34 - $12.73
交易量
55.2K
平均成交量
849.1K
股息收益率
--
每股收益(TTM)
-1645.76
市值
$10.1M
什么是 ACON?
Aclarion, Inc. is a healthcare technology company, which engages in the provision of Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. The company is headquartered in Broomfield, Colorado and currently employs 6 full-time employees. The company went IPO on 2022-04-22. The firm leverages magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. The firm has developed a software application called NOCISCAN. The product uses the existing MRS capabilities of many commercially available scanners to non-invasively analyze the chemical makeup of intervertebral discs in the spine. The software post-processes the MRS exam data and detects the presence of chemical biomarkers that Aclarion, in conjunction with spine researchers at University of California San Francisco (UCSF), have demonstrated to be associated with degenerative pain and structural integrity of the lumbar discs. After processing the MRS exam data, the Company sends the ordering clinician a report that details how to interpret the results of the MRS exam. The platform used to conduct a NOCISCAN involves a diagnostic report called a Nocigram that identifies discs as painful or not.